TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04606784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ampion
Description: Ampion, nebulized for inhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care
Study: NCT01925664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doula
Description: This intervention included doulas providing weekly home visits during the last trimester of pregnancy and up to three months postpartum. Home visits focused on prenatal health, preparation for childbirth, breastfeeding education, and developing a relationship with the baby. Doulas also were present in the hospital during labor, delivery, and postpartum providing emotional support, non-medical comfort measures, and breastfeeding counseling.
Study: NCT03404492

Intervention type: OTHER
Group type: OTHER
Intervention: Stress echocardiography
Description: A stress echocardiography will be performed in addition to the traditional patient care
Study: NCT03075384

Intervention type: PROCEDURE
Intervention: computer-assisted navigation system
Description: The computer-assisted navigation system was applied in treatment of unilateral complicated zygomatic fractures
Study: NCT03041779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium 50Mg Suppository

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol 500Mg Suppository
Study: NCT02044848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01135433

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: oral
Study: NCT04386434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active for Life: Assisted Living
Description: Each intervention session will take place within the assisted living facility twice a week for 12 weeks.~Sessions will begin with 5-10 minutes of walking in the hallway. Participants will be encouraged to walk at their own pace and allowed to take breaks if needed.~Next, behavioral strategies based on the construct of self-efficacy from social cognitive theory and education about physical activity will be delivered. This component is scheduled between the walking and circuit training, lasts 15-20 minutes, and serves as a rest period.~Circuit training will focus on strength and balance. Approximately 8 exercise stations will be set up, and the exercises performed at each station will be changed approximately every 4 weeks. The circuit training will last \~30-40 minutes, with participants moving from one station to the next at their own pace and taking breaks in between.
Study: NCT05570643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPS
Description: This is a non-investigational product. LPS is used as challenge agent to achieve a controlled inflammatory state.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of NaCl 0.9%.
Study: NCT04432831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 16 weeks of this study in order to maintain the masking of the initial faricimab PTI.
Study: NCT00501189

Intervention type: BIOLOGICAL
Intervention: human papillomavirus vaccine L1, type 6,11,16,18
Description: Subjects are those getting gradasil vaccination already. This is really not an intervention
Study: NCT06526403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zero-fluoroscopy ASD closure
Description: Percutaneous ASD closure without fluoroscopy was performed in secundum-type oval-shaped ASD
Study: NCT00539279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy (PE)
Description: PE is a therapy that aims to reduce PTSD symptoms via a systematic exposure to feared memories (by imaginal exposure - repeated narration about the traumatic memory) and situations (by in vivo exposure - engaging in feared but safe activities or facing feared situations).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Training (RT)
Description: RT aims to teach relaxation methods in an effort to reduce anxiety. RT includes Progressive Muscle Relaxation, Imagery Rehearsal, and breathing training.
Study: NCT01561859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy
Description: Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enriched Supportive Therapy
Description: Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are enriched by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis.
Study: NCT02834156

Intervention type: OTHER
Group type: OTHER
Intervention: LP in a seated position then LP in a lying position

Intervention type: OTHER
Group type: OTHER
Intervention: LP in a lying position then LP in a seated position
Study: NCT01316094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study: NCT03909334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Osimertinib 80 mg orally on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Osimertinib 80 mg orally on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Ramucirumab 10 mg/kg intravenously (IV) over 60 minutes for first infusion and if tolerated subsequent infusions may be over 30 minutes
Study: NCT00977314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Sonitus Bone Conduction Hearing System
Description: Comparison of HINT scores (Speech front with noise at better ear) at 30 days tested with the device in place verses with the device removed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoundBite

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoundBite Hearing System
Study: NCT02173678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COMBIVENT® HFA-MDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COMBIVENT® CFC-MDI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo HFA-MDI
Study: NCT03064815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videocapsule endoscopy
Description: Capsule endoscopy is a procedure that uses a tiny wireless camera to take pictures of your digestive tract. A capsule endoscopy camera sits inside a vitamin-size capsule you swallow. As the capsule travels through your digestive tract, the camera takes thousands of pictures that are transmitted to a recorder you wear on a belt around your waist.~Capsule endoscopy helps doctors see inside your small intestine - an area that isn't easily reached with more-traditional endoscopy procedures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videocapsule endoscopy
Description: Capsule endoscopy is a procedure that uses a tiny wireless camera to take pictures of your digestive tract. A capsule endoscopy camera sits inside a vitamin-size capsule you swallow. As the capsule travels through your digestive tract, the camera takes thousands of pictures that are transmitted to a recorder you wear on a belt around your waist.~Capsule endoscopy helps doctors see inside your small intestine - an area that isn't easily reached with more-traditional endoscopy procedures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: Colonoscopy is a test that allows your doctor to look at the inner lining of your large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: Colonoscopy is a test that allows your doctor to look at the inner lining of your large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PROMETHEUS® IBD sgi Diagnostic™
Description: This test combines serologic, genetic, and inflammation markers in a proprietary Smart Diagnostic Algorithm to provide added IBD diagnostic clarity. This test helps physicians differentiate IBD vs. non-IBD and CD vs. UC in one comprehensive blood test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PROMETHEUS® IBD sgi Diagnostic™
Description: This test combines serologic, genetic, and inflammation markers in a proprietary Smart Diagnostic Algorithm to provide added IBD diagnostic clarity. This test helps physicians differentiate IBD vs. non-IBD and CD vs. UC in one comprehensive blood test.
Study: NCT03314389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochet bonnet esthesiometer
Description: Cochet bonnet esthesiometer- To examine sensation
Study: NCT02923466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-IFNβ-NIS
Description: Intratumoral injection of a single dose of VSV-IFNβ-NIS

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-IFNβ-NIS
Description: Intratumoral injection of a single dose of VSV-IFNβ-NIS

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-IFNβ-NIS and avelumab
Description: Intratumoral injection of a single dose of VSV-IFNβ-NIS and intravenous infusion of avelumab
Study: NCT03044158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GeneXpert I
Description: Onsite molecular testing with GeneXpert I as a replacement for microscopy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Process re-design
Description: Research and Uganda NTLP staff will engage health center staff in a discussion of how to re-organize clinical, laboratory and pharmacy services to enable same-day TB diagnosis and treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Performance Feedback
Description: Feedback of TB diagnostic evaluation quality indicators to health center staff
Study: NCT00801190

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HES (130/0.4)
Description: 33 ml/kg i.v. during surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's Lactate
Description: 33 ml/kg i.v.
Study: NCT00322400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Subjects assigned to Arm B, cohorts will receive 75 or 100 mg/m2 of docetaxel (based on cohort assignment) on Day 1 repeated every 21 days (1 cycle). AMG 706 will be administered concurrently on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Subjects assigned to Arm B, cohorts will receive 75 or 100 mg/m2 of docetaxel (based on cohort assignment) on Day 1 repeated every 21 days (1 cycle). AMG 706 will be administered concurrently on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Subjects assigned to Arm B, cohorts will receive 75 or 100 mg/m2 of docetaxel (based on cohort assignment) on Day 1 repeated every 21 days (1 cycle). AMG 706 will be administered concurrently on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Subjects assigned to Arm B, cohorts will receive 75 or 100 mg/m2 of docetaxel (based on cohort assignment) on Day 1 repeated every 21 days (1 cycle). AMG 706 will be administered concurrently on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond.
Study: NCT00951574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin calcium
Description: Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution (placebo)
Description: Pre-filled syringes of 0.4 ml , 1 subcutaneous injection/day (every 24 hours).
Study: NCT03064815

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fecal calprotectin
Description: A stool test to measure inflammation in the gut.
Study: NCT02517476

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional therapy
Description: Any nutritional product and route (i.e. food fortification, oral, enteral, parenteral) is possible to reach goals
Study: NCT01553318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketotifen
Description: After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg by mouth, twice a day or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg by mouth twice a day or the equivalent placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sugar Pill)
Description: After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg BID or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg BID or the equivalent placebo.
Study: NCT02350712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab
Description: Patritumab initial loading dose is 18 mg/kg IV over 60 minutes, followed in Cycle 2 and beyond with a maintenance dose of 9 mg/kg IV over 60 minutes (+/- 10 minutes) every 3 weeks. Infusion time can be extended to a maximum of 120 minutes for participants unable to tolerate the 60-minute infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab
Description: Patritumab initial loading dose is 18 mg/kg IV over 60 minutes, followed in Cycle 2 and beyond with a maintenance dose of 9 mg/kg IV over 60 minutes (+/- 10 minutes) every 3 weeks. Infusion time can be extended to a maximum of 120 minutes for participants unable to tolerate the 60-minute infusion.
Study: NCT01904578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: true accupressure
Description: Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the center line between the ends of the eyebrows.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupressure
Description: Non-acupoints, which were 1 to 3 traditional Chinese unit of length (CUN) away from true acupoints, were used in sham acupressure group.These points were out of the route of energy
Study: NCT00319111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: Oral bosentan~* Initial dose: 62.5 mg twice a day (b.i.d.) for 4 weeks for all patients~* Maintenance dose: 125 mg b.i.d. (62.5 mg b.i.d. if weight \< 40 kg)
Study: NCT04476082

Intervention type: OTHER
Intervention: No intervention - observational study only
Description: No intervention - observational study only
Study: NCT02350712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab initial dose at 400 mg/m2 IV as a 2-hour infusion, followed by 250 mg/m2 IV over 60 minutes weekly.
Study: NCT02265848

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High frequency stimulation
Description: Implanted pulse generator of a spinal cord stimulator will programmed to deliver high frequency stimulation for pain relief. For our purposes, high frequency stimulation will be defined as 1000 hertz.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High frequency stimulation
Description: Implanted pulse generator of a spinal cord stimulator will programmed to deliver high frequency stimulation for pain relief. For our purposes, high frequency stimulation will be defined as 1000 hertz.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency stimulation
Description: Implanted pulse generator of a spinal cord stimulator will programmed to deliver low frequency stimulation for pain relief. Low frequency stimulation will be defined as conventional stimulation pulse generator programming.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency stimulation
Description: Implanted pulse generator of a spinal cord stimulator will programmed to deliver low frequency stimulation for pain relief. Low frequency stimulation will be defined as conventional stimulation pulse generator programming.
Study: NCT02350712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab initial dose at 400 mg/m2 IV as a 2-hour infusion, followed by 250 mg/m2 IV over 60 minutes weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is given as an IV infusion, over 1 hour, 1 hour after the cetuximab infusion, every 3 weeks up to a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is given as an IV-bolus, over 30-60 minutes, every 3 weeks, for a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
Study: NCT01917409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional laryngoscopy
Description: the device is to assist nasotracheal intubation
Study: NCT04475016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 260 mg/m² IV over 30 minutes on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 1200 mg/m² IV over 2 hours on Days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25 mg/m² IV over 2 hours on Days 1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 400 mg IV on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triprilimab
Description: 240 mg IV on Day 1
Study: NCT03379909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin orally at doses up to 1500 mg twice daily for 3 months.
Study: NCT03453489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon C 11 Alpha-methyltryptophan
Description: Undergo AMT-PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo AMT-PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat Etiprate
Description: Given PO
Study: NCT02153801

Intervention type: PROCEDURE
Group type: OTHER
Intervention: During the surgical procedure of Laparoscopic Low Anterior Resection with Total mesorectal Excision .
Description: For High Ligation The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.~For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.~For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: During the surgical procedure of Laparoscopic Low Anterior Resection with Total mesorectal Excision .
Description: For High Ligation The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.~For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.~For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter.
Study: NCT00402701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking School Bus Program
Description: Schoolwide promotion of walk to school. Facilitation of parent-led walking school bus routes.
Study: NCT01834105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liuwei Dihuang Pills
Study: NCT02776332

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Expression of Breastmilk
Description: Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Expression of Breastmilk
Description: Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery